ijms-logo

Journal Browser

Journal Browser

Multiple Myeloma and Chronic Lymphocytic Leukemia: From Molecular Biology to Immunology to Therapy

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (31 March 2021) | Viewed by 5842

Special Issue Editors


E-Mail Website
Guest Editor
Unit of Hematology, “Annunziata” Hospital of Cosenza, Cosenza, Italy
Interests: chronic lymphocytic leukemia; multiple myeloma; chemotherapy; new drugs; prognosis; clinical trials; target therapy; biomarkers

Special Issue Information

Dear Colleagues,

Multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) are both B-cell malignancies, which arise from the clonal expansion of progenitor cells at different stages of B-cell maturity. Clinically, MM and CLL share common features, such as stage‐dependent anaemia, immune deficiency, and late stage unresponsiveness to therapy; indeed, despite the recent introduction of new drugs, both are still incurable. Additionally, both diseases are considered microenvironment-dependent malignancies, in which neoplastic B cells co-evolve together with a supportive tissue microenvironment, leading to chronic inflammation and severe impairment of immune effectors. Specific genomic alterations, such as del17p, identify high-risk patients, which could benefit from specific treatments, while other molecular markers are currently under evaluation.

This Special Issue “Multiple Myeloma and Chronic Lymphocytic Leukemia: from molecular biology to immunology to therapy” of the International Journal of Molecular Sciences, has the objective to develop an updated biological and clinical view on how molecular and immunological alterations impact pathogenesis, disease evolution from asymptomatic early stage disease, therapeutic response and clinical outcome. We welcome original basic, translational and molecular biology-based clinical research articles as well as review articles leading to improvement of the understanding of both MM and CLL disease.

Dr. Cirino Botta
Dr. Massimo Gentile
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • multiple myeloma
  • chronic lymphocytic leukemia
  • P53
  • translational medicine
  • personalized treatment
  • target therapy
  • immuno-oncology
  • biomarkers
  • genetic alteration
  • diagnostics and therapeutics
  • molecular biology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

11 pages, 244 KiB  
Review
Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia
by Veronika Mancikova and Michal Smida
Int. J. Mol. Sci. 2021, 22(11), 5536; https://doi.org/10.3390/ijms22115536 - 24 May 2021
Cited by 26 | Viewed by 5268
Abstract
Chimeric antigen receptor (CAR) T-cell therapy has already achieved remarkable remissions in some difficult-to-treat patients with B-cell malignancies. Although the clinical experience in chronic lymphocytic leukemia (CLL) patients is limited, the proportion of remissions reached in this disease is clearly the lowest from [...] Read more.
Chimeric antigen receptor (CAR) T-cell therapy has already achieved remarkable remissions in some difficult-to-treat patients with B-cell malignancies. Although the clinical experience in chronic lymphocytic leukemia (CLL) patients is limited, the proportion of remissions reached in this disease is clearly the lowest from the spectrum of B-cell tumors. In this review, we discuss the antigenic targets exploited in CLL CAR-T therapy, the determinants of favorable responses, as well as the mechanisms of treatment failure specific to this disease. Full article
Back to TopTop